Cardiovascular

Among people living with HIV receiving antiretroviral therapy, those taking 4-mg pitavastatin daily were 35% less likely than those taking placebo to experience a major cardiovascular event over 5 years of follow-up.

The ASPC Congress on CVD Prevention is taking place in Arlington, Texas, July 21-23. Here, G.B. John Mancini, MD, University of British Columbia, emphasizes the importance of having an international perspective on preventive cardiology.

After replicating the PURE study, researchers found that individuals with higher PURE diet scores had lower risk of death, cardiovascular disease, myocardial infarction, and stroke.

Research suggests that intense physical activity concentrated within 1-2 days and activity more evenly distributed activity across several days are associated with similarly lower risk of cardiovascular outcomes.

The FDA has approved the first over the counter (OTC) birth control pill Thursday; the US Chamber of Commerce has filed a motion for preliminary injunction on the Medicare Drug Price Negotiation program; individuals living in historically redlined areas are likely to have worse heart health.

Research was conducted by multiple laboratories in the Global Diagnostics Network and included more than 460 million lipid test results from 17 countries to determine risk of cardiovascular disease (CVD).

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.

Dr Slipczuk concludes our discussion by detailing healthcare disparities commonly seen within ASCVD treatment.

A cardiology expert considers the future of lipid management within health systems and ways they can improve engagement from all parties.

Dr Slipczuk explores quality metrics, elaborating on ways to improve and align them with the latest cardiology treatment guidelines and payer considerations.

Dr Slipczuk offers strategies for sharing information and guiding appropriate ASCVD treatment both within and outside closed health systems.

Leandro N. Slipczuk, MD, PhD, details his organization’s effort to support uptake of PCSK9 inhibitors in the inpatient setting.

Dr Leandro N. Slipczuk highlights the importance of cardiovascular treatment guidelines when deciding on patient care for those with ASCVD.

Three cardiovascular experts discuss the future of lipid management for patients with high-risk ASCVD.

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.

Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

People with high risk of obstructive sleep apnea presented with significant changes in key arteries indicative of accelerated vascular aging, a known contributor to cardiovascular disease (CVD).

Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.

Patients with chronic cardiac conditions benefited from a health care program that strengthened collaboration between general practitioners and cardiology specialists in Baden-Wuerttemberg, Germany.

Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.

The top 5 most-read conference stories of 2020 on AJMC.com included stories about study results on the impact that new therapies are having on cardiovascular and renal health.